Pharmaceutical giant Pfizer announced Thursday the completion of its acquisition of Seagen Inc., a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.

“Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion,” Pfizer said in a press release.

According to the press release, the acquisition “further establishes Pfizer as a leading oncology company poised to accelerate the next generation of breakthrough treatments for people with cancer.”

“Cancer remains a leading cause of death, and one in three people in the U.S. will receive a cancer diagnosis in their lifetime. With one of the largest investments in Pfizer’s history, we are going all in on cancer with the goal of delivering breakthroughs that drastically improve the lives of people with cancer,” said Dr. Albert Bourla, Pfizer Chairman and Chief Executive Officer.

“With Seagen’s proprietary, world-leading Antibody-Drug Conjugate (ADC) technology, together with the scale and strength of Pfizer’s capabilities and expertise, we are poised to change the cancer treatment paradigm. We believe Oncology will be a significant growth driver for Pfizer and contribute meaningfully to the achievement of our near- and long-term financial goals,” he added.

From Pfizer:

Seagen is a world-leader in ADC technology, a transformative modality that is emerging as a powerful tool across a broad range of cancers designed to preferentially kill cancer cells and limit off-target toxicities. With the addition of Seagen’s four in-line medicines, ADCETRIS® (brentuximab vedotin), PADCEV® (enfortumab vedotin), TIVDAK® (tisotumab vedotin) and TUKYSA® (tucatinib), Pfizer’s industry-leading Oncology portfolio now includes over 25 approved medicines and biosimilars across more than 40 indications, including nine medicines that are either blockbuster or have the potential to be blockbuster.

With the addition of Seagen, Pfizer’s Oncology pipeline has doubled in size with 60 programs spanning multiple modalities, including ADCs, small molecules, bispecifics and other immunotherapies. Moving forward, Pfizer will leverage its leading protein engineering and medicinal chemistry capabilities to advance Seagen’s ADC technology, unlocking potential novel combinations and next-generation biologics.

“This is a great day for Pfizer, and, more importantly, for people living with cancer, as we bring together the game-changing science and top talent of Seagen and Pfizer to form a leading Oncology organization,” said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer. “Driven by science and a passion for improving and extending patients’ lives, together, we will work with urgency towards our common purpose to deliver transformative cancer medicines and bring new hope to people living with cancer everywhere.”

As previously disclosed, to address U.S. Federal Trade Commission concerns, Pfizer has chosen to irrevocably donate the rights of royalties from sales of Bavencio® (avelumab) in the U.S. to the American Association for Cancer Research (AACR). This unrestricted donation will support AACR in its mission to prevent and cure cancer through research, education, communication, collaboration, science policy, and funding for cancer research.

“Pfizer said on Wednesday that it anticipates products gained from the Seagen buyout will account for $3.1 billion in revenue in 2024. By 2030, Pfizer expects that figure to swell to $10 billion,” Fierce Pharma wrote.

Pfizer’s $43 billion acquisition is the “largest M&A transaction in the biopharma industry since AbbVie snatched up Allergan for $63 billion in 2019,” the outlet noted.

More from Fierce Pharma:

Companies developing ADC therapies have become hot properties this year as other Big Pharma players such as AbbVie, Merck and Bristol Myers Squibb have followed Pfizer’s lead. The technology has been a breakthrough with its ability to deliver cancer-busting treatment to tumors with little damage to other tissues.

“In addition to expanding our portfolio and leading the next generation of cancer breakthroughs, we also expect Seagen to contribute meaningfully to our goal of accelerating near-term and long-term financial growth,” Bourla said.

“Pfizer’s deal begins the start of a new chapter for the New York company which saw its value skyrocket with its success in 2021-22 selling COVID-19 products Comirnaty and Paxlovid,” Fierce Pharma added.

According to Dr. William Makis, Pfizer’s acquisition is more sinister than what it appears at face value.

Makis writes:

Pfizer completes $43 Billion acquisition of Seagen on Dec.14, 2023 – becomes largest oncology company to treat most TURBO CANCERS caused by mRNA Vaccines – deep dive into the sinister aspects of this very bizarre deal.

Pfizer OVERPAYS $43 billion on small Cancer Drug Company that barely makes $2 billion a year.

Pfizer doesn’t need the cash. It will also issue $31 billion in debt to purchase it.

Everyone is taking this at face value. But something very sinister lurks in the details of this deal.

Pfizer (and Moderna) COVID-19 mRNA Vaccines cause Turbo Cancers. Based on my published description of 100s of Turbo Cancer cases in over 30 articles:

Here are the Top 5 Turbo Cancers we will see by numbers in mRNA Vaccinated people:

Lymphoma (various types)
Brain Cancers (mostly glioblastoma)
Breast Cancer (mostly triple negative, Stage 3/4)
Colon Cancer (Stage 4)
Lung Cancer (Stage 4)

Rounding out the Top 10 Turbo Cancers by # of people affected (no particular order):

leukemias (worst prognosis)
melanomas (Stage 4)
sarcomas (Stage 3,4)
testicular/ovarian (rapid progression, Stage 1-4)
kidney (RCC Stage 4)

Pfizer’s new acquisition takes them from being able to treat 2 of these Turbo Cancers, to being able to treat 7 out of 10. Not bad.

But there’s more.

Pfizer CEO Albert Bourla did a media interview tour about the $43 Billion Cancer drug deal and this is what he has to say:

– 33% of people WILL get cancer (he’s certain)
– entire families WILL be affected (he’s certain)
– The new cancer treatments are like “missiles” that will target “most” cancers
– he will produce them AT A SCALE THAT HAS NOT BEEN SEEN BEFORE.
– 2025
– “We have a Global Network”
– ” we have very quick way of completing clinical trials”
– will be produced “AT SCALE”, “just like mRNA”

Think about what he is telegraphing. Read the above again.

Why would any company need to produce cancer treatments “AT SCALE”?

Seeking Alpha analysis theorizes it would take Pfizer at least a decade just to break even from this deal.

Financially, this $43 billion Acquisition makes NO SENSE for Pfizer.

Unless something else happens…

Read more about the “turbo cancers” Makis refers to at the link. 

 

Join The Conversation. Leave a Comment.


We have no tolerance for comments containing violence, racism, profanity, vulgarity, doxing, or discourteous behavior. If a comment is spam, instead of replying to it please click the ∨ icon below and to the right of that comment. Thank you for partnering with us to maintain fruitful conversation.